Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions

SIMPLE SUMMARY: HER2-low breast cancer (BC) accounts for more than half of breast cancer patients. Anti-HER2 therapy has been ineffective in HER2-low BC, for which palliative chemotherapy is the main treatment modality. The definitive efficacy of T-Dxd in HER2-low BC breaks previous treatment strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Heng-Zhou, Han, Jie-Rong, Fu, Xi, Ren, Yi-Feng, Li, Zhuo-Hong, You, Feng-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367369/
https://www.ncbi.nlm.nih.gov/pubmed/35954438
http://dx.doi.org/10.3390/cancers14153774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367369/
https://www.ncbi.nlm.nih.gov/pubmed/35954438
http://dx.doi.org/10.3390/cancers14153774

Ejemplares similares